Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2023

Open Access 01-12-2023 | Statins | Research article

Assessment of redundant randomized clinical trials among patients with ST segment elevation myocardial infarction

Authors: Yuanxi Jia, Jun Liang, Wenyao Wang, Xin Wei, Shaoming Xiao, Karen A. Robinson

Published in: BMC Medicine | Issue 1/2023

Login to get access

Abstract

Background

Redundant clinical trials waste resources and unnecessarily put patients at risk for harm. The objectives of the study were to assess redundant randomized clinical trials (RCTs) conducted in mainland China or the USA among patients with ST segment elevation myocardial infarction (STEMI) and estimate the harm to patients enrolled in redundant RCTs.

Methods

We searched bibliographic databases for eligible RCTs comparing a routine therapy with a placebo or no treatment among patients with STEMI in mainland China or the United States. The routine therapy for STEMI included reperfusion (percutaneous coronary intervention or fibrinolytic therapy), P2Y12 receptor inhibitors, statins, and anticoagulants. Redundant RCTs were defined as those initiated or continued recruiting new patients 1 year after the experimental intervention was established as routine therapy in clinical practice guidelines. Cumulative meta-analyses were conducted to confirm the efficacy of these routine therapies.
The primary outcome was the number of extra major adverse cardiac events (MACEs) attributable to the deprivation of routine therapies among patients in the control groups of redundant RCTs—that is, the number of extra MACEs that could have been prevented had these patients received routine therapy.

Results

Nine hundred eighty-three eligible RCTs conducted in mainland China were identified, of which 775 (78.8%) were redundant. None of the five eligible RCTs conducted in the United States were redundant. All redundant RCTs have reiterated the benefits of routine therapies for patients with STEMI, while none were cited by the 2019 clinical practice guideline for the management of STEMI.
The 18,819 patients in the control groups of redundant RCTs experienced 3305 (95% CI: 3169–3441) extra MACEs, including 1091 (1014–1165) deaths, 576 (519–633) recurrent myocardial infarctions, 31 (19–42) revascularizations, 39 (23–54) strokes, 744 (679–810) heart failures, and 823 (754–893) patients with recurrent or exacerbated angina pectoris. Cumulative meta-analyses confirmed the efficacy of the routine therapies among patients in mainland China and supported using practice guidelines to define redundant RCTs.

Conclusions

Redundant RCTs conducted in mainland China have resulted in unnecessary MACEs among patients with STEMI. While the reasons behind redundant RCTs need to be further investigated, these results suggest potential research waste and violation of research ethics.
Appendix
Available only for authorised users
Literature
1.
Speich B, Schur N, Gryaznov D, von Niederhäusern B, Hemkens LG, Schandelmaier S, et al. Resource use, costs, and approval times for planning and preparing a randomized clinical trial before and after the implementation of the new Swiss human research legislation. PLoS One. 2019;14(1):e0210669.PubMedPubMedCentralCrossRef
2.
Johnston SC, Rootenberg JD, Katrak S, Smith WS, Elkins JS. Effect of a US National Institutes of Health programme of clinical trials on public health and costs. Lancet. 2006;367(9519):1319–27.PubMedCrossRef
3.
Millum J, Grady C. The ethics of placebo-controlled trials: methodological justifications. Contemp Clin Trials. 2013;36(2):510–4.PubMedCrossRef
4.
Freedman B. Clinical equipoise and the ethics of clinical research. N Engl J Med. 1987;317:141–5.PubMedCrossRef
5.
Borgerson K. Redundant, secretive, and isolated: when are clinical trials scientifically valid? Kennedy Inst Ethics J. 2014;24(4):385–411.PubMedCrossRef
6.
Bolland MJ, Avenell A, Grey A. Assessment of research waste part 1: an exemplar from examining study design, surrogate and clinical endpoints in studies of calcium intake and vitamin D supplementation. BMC Med Res Methodol. 2018;18(1):1–10.
7.
Bolland MJ, Grey A, Avenell A. Assessment of research waste part 2: wrong study populations-an exemplar of baseline vitamin D status of participants in trials of vitamin D supplementation. BMC Med Res Methodol. 2018;18(1):1–14.
8.
Vergara-Merino L, Verdejo C, Franco JVA, Liquitay CE, Urrútia G, Klabunde R, et al. Registered trials address questions already answered with high-certainty evidence: A sample of current redundant research. J Clin Epidemiol. 2021;134:89–94.PubMedCrossRef
9.
Tollefson J. China declared world's largest producer of scientific articles. Nature. 2018;553(7686):390-1.
10.
11.
12.
Jia Y, Wen J, Qureshi R, Ehrhardt S, Celentano DD, Wei X, et al. Effect of redundant clinical trials from mainland China evaluating statins in patients with coronary artery disease: cross sectional study. BMJ. 2021;372:n48.PubMedPubMedCentralCrossRef
13.
O'gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, De Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):e78–e140.PubMedCrossRef
14.
Tollefson J. China declared world’s largest producer of scientific articles. Nature. 2018;553(7686):390–1.PubMedCrossRef
15.
Vandenbroucke JP, Von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4(10):e297.PubMedPubMedCentralCrossRef
16.
Chinese Society of Cardiology. 2019 Chinese Society of Cardiology (CSC) guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction. Chin J Cardiol. 2019;47(10):18.
17.
Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2011;58(23):2432–46.PubMedCrossRef
18.
Chinese Society of Cardiology. Guidelines for the diagnosis and management of patients with non-ST segment elevation myocardial infarction. Chin J Cardiol. 2017;45(5):18.
19.
Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions: John Wiley & Sons; 2019.CrossRef
20.
Chinese Society of Cardiology. Guideline for diagnosis and treatment of patients with ST-elevation myocardial infarction. Chin J Cardiol. 2010;38(8):675–90.
21.
Chinese Society of Cardiology. Guideline for diagnosis and treatment of patients with unstable angina and non- ST-segment elevation myocardial infarction (no abstract). Chin J Cardiol. 2007;35(4):295–304.
22.
Members WC, Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). J Am Coll Cardiol. 2004;44(3):671–719.CrossRef
23.
Guidelines ACoCAHATFoP, Society DiCWtCC, Physicians EbtAAoF, Evidence WGtRN, Update the ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction WoBotWC, Antman EM, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction. J Am Coll Cardiol. 2008;51(2):210–47.CrossRef
24.
Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, et al. PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. Syst Rev. 2021;10(1):1–19.CrossRef
25.
Jia Y, Huang D, Wen J, Wang Y, Rosman L, Chen Q, et al. Assessment of language and indexing biases among Chinese-sponsored randomized clinical trials. JAMA Netw Open. 2020;3(5):e205894.PubMedPubMedCentralCrossRef
26.
Jia Y, Huang D, Wen J, Qureshi R, Wang Y, Rosman L, et al. Assessment of duplicate publication of chinese-sponsored randomized clinical trials. JAMA Netw Open. 2020;3(12):e2027104.PubMedPubMedCentralCrossRef
27.
Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.PubMedPubMedCentralCrossRef
28.
29.
Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med. 1992;327(4):248–54.PubMedCrossRef
30.
Clarke M, Brice A, Chalmers I. Accumulating research: a systematic account of how cumulative meta-analyses would have provided knowledge, improved health, reduced harm and saved resources. PLoS One. 2014;9(7):e102670.PubMedPubMedCentralCrossRef
31.
Hackler E III, Lew J, Gore MO, Ayers CR, Atzler D, Khera A, et al. Racial differences in cardiovascular biomarkers in the general population. J Am Heart Assoc. 2019;8(18):e012729.PubMedPubMedCentralCrossRef
32.
33.
Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting–enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med. 2001;344(18):1351–7.PubMedCrossRef
34.
Guanghui Jin YZ, Shao S, Qin X. Survery on the current research activities in general practitioners[全科医生科研工作现状调查研究]. Contin. Med Educ. 2017;31(12):2.
35.
Liao J. Investigation and analysis on the current situation of clinicians’ scientific research cognition in a hospital of class A grade three. Modern Hosp Manage. 2020;18(1):5.
36.
Renjie Lu HY, Ruan L, Chen Y, Zhang Y. Investigation on status of scientific research among young doctors in a infectious disease hospital of Changzhou city. Med Soc (Berkeley). 2018;31(11):3.
37.
Zhang L, Sivertsen G. The new research assessment reform in China and its implementation. Sch Asses Rep. 2020;2(1):3.
38.
Zhang Z, Winston GP, Zhao H-T, Oei EH, Ai Q, Loffroy R, et al. Focus on China: should clinicians engage in research? and lessons from other countries. Quant Imaging Med Surg. 2014;4(5):413.PubMedPubMedCentral
39.
Clarke M, Hopewell S, Chalmers I. Clinical trials should begin and end with systematic reviews of relevant evidence: 12 years and waiting. Lancet. 2010;376(9734):20–1.PubMedCrossRef
40.
Krleža-Jerić K, Chan A-W, Dickersin K, Sim I, Grimshaw J, Gluud C. Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1). BMJ. 2005;330(7497):956–8.PubMedPubMedCentralCrossRef
41.
42.
Clark J, Smith R. Firm action needed on predatory journals. BMJ. 2015;350:h210.
43.
Wu T, Li Y, Bian Z, Liu G, Moher D. Randomized trials published in some Chinese journals: how many are randomized? Trials. 2009;10(1):1–8.CrossRef
44.
Tong Z, Li F, Ogawa Y, Watanabe N, Furukawa TA. Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National Knowledge Infrastructure (CNKI): a literature and telephone interview study. BMC Med Res Methodol. 2018;18(1):1–11.CrossRef
45.
Jia Y, Huang D, Wen J, Liang J, Qureshi R, Wang Y, et al. Association between switching of primary outcomes and reported trial findings among randomized drug trials from China. J Clin Epidemiol. 2021;132:10–7.PubMedCrossRef
46.
Else H, Van Noorden R. The fight against fake-paper factories that churn out sham science. Nature. 2021;591(7851):516–9.PubMedCrossRef
47.
Frandsen TF, Eriksen MB, Hammer DMG, Christensen JB, Wallin JA. Using Embase as a supplement to PubMed in Cochrane reviews differed across fields. J Clin Epidemiol. 2021;133:24–31.PubMedCrossRef
48.
49.
50.
51.
World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4.
Metadata
Title
Assessment of redundant randomized clinical trials among patients with ST segment elevation myocardial infarction
Authors
Yuanxi Jia
Jun Liang
Wenyao Wang
Xin Wei
Shaoming Xiao
Karen A. Robinson
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2023
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-023-02749-2

Other articles of this Issue 1/2023

BMC Medicine 1/2023 Go to the issue

Research article

Cross-talks between gut microbiota and tobacco smoking: a two-sample Mendelian randomization study

Research article

Faecal haemoglobin concentrations are associated with all-cause mortality and cause of death in colorectal cancer screening

Correspondence

The CARAMAL study could not assess the effectiveness of rectal artesunate in treating suspected severe malaria

Research article

Genetically predicted plasma levels of amino acids and metabolic dysfunction-associated fatty liver disease risk: a Mendelian randomization study

Research article

Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with glioma: a meta-analysis

Research article

Ethnic differences in COVID-19 mortality in the second and third waves of the pandemic in England during the vaccine rollout: a retrospective, population-based cohort study